CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Artificial Intelligence for Medicine : An Applied Reference for Methods and Applications
2024 S. Ben- David, G. Curigliano, D. Koff, B.A. Jereczek, D. LA TORRE, G. Pravettoni
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2024 B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito, S. Siena, P. Aftimos, I. Anderson, G. Curigliano, M. de Miguel, M. Kalra, D. Oh, J.O. Park, S. Postel-Vinay, S.Y. Rha, T. Satoh, I. Spanggaard, F. Michelini, A. Smith, K.K. Machado, C. Saura
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment
2024 G. Corso, N. Fusco, E. Guerini-Rocco, M.C. Leonardi, C. Criscitiello, P. Zagami, E. Nicolo, G. Mazzarol, C. La Vecchia, F. Pesapane, C. Zanzottera, P. Tarantino, S. Petitto, B. Bianchi, G. Massari, A. Boato, A. Sibilio, A. Polizzi, G. Curigliano, A.M. De Scalzi, F. Lauria, B. Bonanni, M. Marabelli, A. Rotili, L. Nicosia, A. Albini, M. Calvello, R.A. Mukhtar, M.E. Robson, V. Sacchini, G. Rennert, V. Galimberti, P. Veronesi, F. Magnoni
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2024 S. Loibl, F. André, T. Bachelot, C.H. Barrios, J. Bergh, H.J. Burstein, M.J. Cardoso, L.A. Carey, S. Dawood, L. Del Mastro, C. Denkert, E.M. Fallenberg, P.A. Francis, H. Gamal-Eldin, K. Gelmon, C.E. Geyer, M. Gnant, V. Guarneri, S. Gupta, S.B. Kim, D. Krug, M. Kater, I. Meattini, M. Morrow, W. Janni, S. Paluch-Shimon, A. Partridge, P. Poortmans, L. Pusztai, M.M. Regan, J. Sparano, T. Spanic, S. Swain, S. Tjulandin, M. Toi, D. Trapani, A. Tutt, B. Xu, G. Curigliano, N. Harbeck
Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer
2024 D. Massa, C. Vernieri, L. Nicolè, C. Criscitiello, F. Boissière-Michot, S. Guiu, A. Bobrie, G. Griguolo, F. Miglietta, A. Vingiani, R. Lobefaro, B. Taurelli Salimbeni, C. Pinato, F. Schiavi, S. Brich, C. Pescia, N. Fusco, G. Pruneri, M. Fassan, G. Curigliano, V. Guarneri, W. Jacot, M.V. Dieci
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Biomarkers for antibody-drug conjugates in solid tumors
2024 J. Katrini, L. Boldrini, C. Santoro, C. Valenza, D. Trapani, G. Curigliano
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center
2024 C. Valenza, T.M. De Pas, A. Gaeta, G. Castellano, C. Santoro, A. Corona, G. Chiappini, G. Vivanet, D. Trapani, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Pennacchioli, G. Curigliano
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories
2024 F. Pepe, K. Venetis, G. Cursano, C. Frascarelli, P. Pisapia, D. Vacirca, C. Scimone, A. Rappa, G. Russo, E. Mane, F. Pagni, I. Castellano, G. Troncone, C.D. Angelis, G. Curigliano, E. Guerini-Rocco, U. Malapelle, N. Fusco
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
2024 E. Guerini-Rocco, K. Venetis, G. Cursano, E. Mane, C. Frascarelli, F. Pepe, M. Negrelli, E. Olmeda, D. Vacirca, A. Ranghiero, D. Trapani, C. Criscitiello, G. Curigliano, C. Rolfo, U. Malapelle, N. Fusco
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores
2024 M. Ivanova, C. Frascarelli, B. Cerbelli, M.G. Pignataro, A. Pernazza, K. Venetis, E. Sajjadi, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, P. Graziano, M. Martini, G. D'Amati, N. Fusco
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates
2024 S. Natangelo, D. Trapani, C. Koukoutzeli, L. Boscolo Bielo, G. Marvaso, B.A. Jereczek-Fossa, G. Curigliano
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
2024 M. Cobanaj, C. Corti, E.C. Dee, L. Mccullum, L. Boldrini, I. Schlam, S.M. Tolaney, L.A. Celi, G. Curigliano, C. Criscitiello
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2024 L. Cantini, D. Trapani, L. Guidi, L. Boscolo Bielo, R. Scafetta, M. Koziej, L. Vidal, K.S. Saini, G. Curigliano
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy
2024 K. Venetis, C. Pescia, G. Cursano, C. Frascarelli, E. Mane, E. De Camilli, E. Munzone, S. Dellapasqua, C. Criscitiello, G. Curigliano, E. Guerini Rocco, N. Fusco
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
2024 L. Arecco, M. Bruzzone, R. Bas, H.J. Kim, A. Di Meglio, R. Bernstein-Molho, F.S. Hilbers, K. Pogoda, E. Carrasco, K. Punie, J. Bajpai, E. Agostinetto, N. Lopetegui-Lia, A.H. Partridge, K.A. Phillips, A. Toss, C. Rousset-Jablonski, G. Curigliano, T. Renaud, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, F.J. Couch, M.V. Dieci, A. Matikas, M. Rozenblit, D. Aguilar-Y Méndez, L. De Marchis, F. Puglisi, A. Fabi, S.L. Graff, I. Witzel, A. Rodriguez Hernandez, A. Fontana, R. Pesce, R. Duchnowska, H.L. Pais, V. Sini, E. Sokolović, E. de Azambuja, M. Ceppi, E. Blondeaux, M. Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
2024 F. Schettini, E. Blondeaux, C. Molinelli, R. Bas, H.J. Kim, A. Di Meglio, R. Bernstein Molho, S.C. Linn, K. Pogoda, E. Carrasco, K. Punie, E. Agostinetto, N. Lopetegui-Lia, K. Phillips, A. Toss, C. Rousset-Jablonski, M. Acheritogaray, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, M.V. Dieci, A. Matikas, M. Rozenblit, C. Villarreal-Garza, L. De Marchis, F. Puglisi, L. Vasconcelos de Matos, M. Mariño, L. Teixeira, R. Graffeo, A. Rognone, A. Chirco, N. Antone, Y. Abdou, M. Marhold, I. Božović-Spasojević, A. Cortés Salgado, L. Carmisciano, M. Bruzzone, G. Curigliano, A. Prat, M. Lambertini
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
2023 B. Kiesewetter, U. Dafni, E.G.E. de Vries, J. Barriuso, G. Curigliano, V. González-Calle, M. Galotti, B. Gyawali, B.J.P. Huntly, U. Jäger, N.J. Latino, L. Malcovati, S.F. Oosting, G. Ossenkoppele, M. Piccart, M. Raderer, L. Scarfò, D. Trapani, C.C. Zielinski, R. Wester, P. Zygoura, E. Macintyre, N.I. Cherny
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano